GWPH - GW Pharmaceuticals plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
135.75
-3.51 (-2.52%)
At close: 4:00PM EST

135.48 -0.27 (-0.20%)
After hours: 4:16PM EST

Stock chart is not supported by your current browser
Previous Close139.26
Open140.50
Bid133.66 x 800
Ask136.65 x 1100
Day's Range133.00 - 142.99
52 Week Range90.14 - 179.65
Volume640,432
Avg. Volume508,693
Market Cap4.391B
Beta (3Y Monthly)3.43
PE Ratio (TTM)N/A
EPS (TTM)-10.61
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est173.17
Trade prices are not sourced from all markets
  • Cara Therapeutics: Earnings Trends and Recent Developments
    Market Realist10 hours ago

    Cara Therapeutics: Earnings Trends and Recent Developments

    Cara Therapeutics Has Risen ~18% in January(Continued from Prior Part)Earnings trendsIn the first nine months of 2018, Cara Therapeutics (CARA) reported a net income and EPS of -$53.4 million and -$1.54, respectively—compared to -$43.9 million and

  • Cara Therapeutics: A Financial Overview in January
    Market Realist12 hours ago

    Cara Therapeutics: A Financial Overview in January

    Cara Therapeutics Has Risen ~18% in January(Continued from Prior Part)Revenue trendsIn the first nine months of 2018, Cara Therapeutics (CARA) generated revenues of $7.9 million—compared to $911,000 during the same period the previous year. In

  • ACCESSWIRE12 hours ago

    4 Marijuana Stocks Setting The Standard On Wednesday (1/23/19)

    CORAL GABLES, FL / ACCESSWIRE / January 23, 2019 / The marijuana stock market has remained incredibly interesting and full of life for the better part of two years at this point. With countless new innovations and updates to everything from cannabis legislation to nuanced applications of products in treatment and healthcare, it seems as though we are entering a new phase of cannabis throughout the whole market. As we enter the closing weeks of January, Premier Health Group (OTC:PHGRF) (CSE:PHGI), Canopy Growth Corp. (WEED.TO) (TSX:WEED), GW Pharmaceuticals plc (GWPH), and Cronos Group Inc. (CRON) are four pot stocks representing companies looking to push the limits of their sector.

  • Cara Therapeutics Has Risen ~18% in January
    Market Realist13 hours ago

    Cara Therapeutics Has Risen ~18% in January

    Cara Therapeutics Has Risen ~18% in JanuaryStock performance Cara Therapeutics’ (CARA) stock price reached $15.35 on January 18—compared to $13.00 when the market closed on December 31, which represents ~18% growth YTD (year-to-date). On January

  • The Zacks Analyst Blog Highlights: GW Pharmaceuticals, Innovative Industrial Properties, KushCo and Canopy Growth
    Zacks15 hours ago

    The Zacks Analyst Blog Highlights: GW Pharmaceuticals, Innovative Industrial Properties, KushCo and Canopy Growth

    The Zacks Analyst Blog Highlights: GW Pharmaceuticals, Innovative Industrial Properties, KushCo and Canopy Growth

  • ACCESSWIREyesterday

    4 Marijuana Stocks Getting A Boost From Today's Headlines

    With the global medical marijuana market predicted to reach $55.0 billion by 2024, according to a new research study published by Global Market Insights, Inc, it stands to reason that companies with the ability to combine the complex medical applications of cannabis with integrative healthcare frameworks could create potential opportunities from entering the nascent marijuana industry. ), and GW Pharmaceuticals plc (GWPH) are four pot stocks representing companies helping the whole of their industry move forward. Premier Health Group (PHGRF) (PHGI) is a company focused on redesigning how medical care is received and implementing nuanced practical applications for cannabis products in the healthcare space.

  • 4 Marijuana Stocks That Look Profitable in 2019
    Zacks2 days ago

    4 Marijuana Stocks That Look Profitable in 2019

    Global consumer marijuana spending is estimated to climb 38% to $16.9 billion this year, up from a projected $12.2 billion last year, $9.5 billion in 2017, and $6.9 billion in 2016.

  • Benzinga3 days ago

    Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week

    There were numerous political announcements shaping the industry last week, with a Michigan state board ruling that more than 60 medical cannabis dispensaries that had to close at the end of last year ...

  • Benzinga6 days ago

    Jim Cramer Advises His Viewers On Brink's, Medtronic And More

    On CNBC's "Mad Money Lightning Round" , Jim Cramer said there was really no reason for a sell-off in Brink's Company (NYSE: BCO ). He thinks the quarter was great and he wants to buy the stock. ...

  • ACCESSWIRE6 days ago

    4 Marijuana Stocks Looking To Have A Banner Month

    CORAL GABLES, FL / ACCESSWIRE / January 17,2019 / Marijuana stocks have become one of the hottest topics in the news over the course of the past few years. With the new year in full swing, Leafbuyer Technologies Inc (LBUY), Cronos Group Inc (CRON) (CRON), GW Pharmaceuticals plc (GWPH), and Charlotte's Web Holdings Inc (CWBHF) re 4 pot stocks that could make moves on Thursday. Leafbuyer Technologies Inc (LBUY) is a company worth looking into given that the Company's online platform is the most comprehensive source for cannabis deals and specials, commonly referred to as the "Priceline of Pot," by several sources well-versed in the industry.

  • These Three Cannabis Stocks Are in the Green Today
    Market Realist6 days ago

    These Three Cannabis Stocks Are in the Green Today

    These Three Cannabis Stocks Are in the Green TodayINSYS TherapeuticsToday, INSYS Therapeutics (INSY) is trading at $4.69, up ~8.80% from its close of $4.31 on January 16. On January 16, INSY rose ~2.62% to $4.31 from its previous close of $4.20 on

  • GlobeNewswire7 days ago

    Mugglehead reveals a number of stocks set to take advantage of hemp

    It’s one of the world’s fastest growing plants—a separate species of the cannabis sativa genus that, due to its 0.3% tetrahydrocannabinol (THC) content, makes it literally almost impossible to get high from smoking it. Just weeks ago, U.S. President Trump signed the 2018 Farm Bill into law. The newly revamped bill legalizes industrial hemp in the U.S., and in doing so not only makes hemp and CBD eligible for lucrative federal crop insurance, but also removes CBD from the Controlled Substances Act.

  • These Cannabis Stocks Are Soaring in January
    Market Realist8 days ago

    These Cannabis Stocks Are Soaring in January

    These Cannabis Stocks Are Soaring in JanuaryCannabis stock trendsCannabis stock CannTrust Holdings (CNTTF) rose to $6.0 on January 15 from $4.8 at the close of market on December 31, 2018, representing a rise of ~25% in the first half of January

  • ACCESSWIRE8 days ago

    4 Marijuana Stocks Leading Tuesday's Bull Charge

    CORAL GABLES, FL / ACCESSWIRE / January 15,2019 / Marijuana stocks have had quite a solid week during the beginning of January. American Premium Water Corporation (HIPH), GW Pharmaceuticals plc (GWPH), Cronos Group Inc (CRON) (CRON), and Charlotte's Web Holdings Inc (CWBHF) are 4 pot stocks that are bringing the heat. American Premium Water Corporation (HIPH) is a company you may not have heardof, but could benefit from taking a look at.

  • The Must-See Marijuana Commentary From the U.S. Surgeon General
    Motley Fool12 days ago

    The Must-See Marijuana Commentary From the U.S. Surgeon General

    The nation's top doctor shows that calls for cannabis reform aren't falling on deaf ears.

  • How Is INSYS Therapeutics Financially Positioned in January?
    Market Realist12 days ago

    How Is INSYS Therapeutics Financially Positioned in January?

    Cannabis Stock INSYS Therapeutics Is on the Rise in January (Continued from Prior Part) ## Revenue trends In the first nine months of 2018, INSYS Therapeutics’ net revenues declined ~40% YoY to reach $109.2 million from $65.7 million. In the third quarter, the company’s revenues declined ~40% YoY to reach $18.3 million from $30.7 million. Wall Street analysts estimate that INSYS Therapeutics is expected to generate revenues of $17.95 million in the fourth quarter of fiscal 2018, which represents a ~42.99% YoY decline. Analysts also estimate that INSYS Therapeutics will report net revenues of $83.74 million for fiscal 2018, which represents a ~40.48% YoY decline. Analysts estimate that GW Pharmaceuticals (GWPH) and Cara Therapeutics (CARA), INSYS Therapeutics’ peers in the cannabinoid drugs market, will report net revenues of $8.7 million and $10.9 million, respectively. GW Pharmaceuticals is expected to deliver ~13.52% YoY revenue growth in fiscal 2018. INSYS Therapeutics and Lunatus signed a licensing agreement for the commercialization of Subsys in the Middle East market. The agreement could boost INSYS Therapeutics’ global footprint and business growth. ## Expenditure trends In the first nine months of 2018, INSYS Therapeutics’ cost of revenue amounted to $8.2 million compared to $16.0 million in the same period the prior year. Wall Street analysts anticipate INSYS Therapeutics’ cost of revenue to be around $9.7 million in fiscal 2018. In the first nine months of 2018, INSYS Therapeutics’ net expenses in sales and marketing (or S&M) amounted to $25.5 million compared to $41.7 million in the same period the prior year. INSYS Therapeutics reported R&D (research & development) and G&A (general & administrative) expenses of $43.2 million and $29.3 million, respectively, compared to $46.6 million and $31.8 million in the same period the prior year. Wall Street analysts estimate that the company’s S&M, G&A, and R&D expenditure will be around $32.49 million, $89.50 million, and $58.78 million, respectively, in fiscal 2018. Continue to Next Part Browse this series on Market Realist: * Part 1 - Cannabis Stock INSYS Therapeutics Has Risen 28% in January * Part 3 - How INSYS Therapeutics’ Earnings Were Trending

  • Cannabis Stock INSYS Therapeutics Has Risen 28% in January
    Market Realist12 days ago

    Cannabis Stock INSYS Therapeutics Has Risen 28% in January

    On January 10, INSYS Therapeutics stock closed at $4.49, which represents ~28% growth from its stock price of $3.50 at the close of market on December 31. On January 2, 2019, INSYS Therapeutics stock price grew ~24.29% to reach $4.35 from its prior day close of $3.50 on December 31, 2018.

  • ACCESSWIRE13 days ago

    These 4 Marijuana Stocks Are Hitting Their Stride

    CORAL GABLES, FL / ACCESSWIRE / January 11,2019 / The marijuana industry has been anything but safe over the course of the past year to two years, during the course of which top players in the industry saw huge boosts in investor interest. ), OrganiGram Holdings Inc (OGRMF) (OGI.V), Namaste Technologies Inc (NXTTF), and GW Pharmaceuticals Plc (GWPH) are 4 pot stocks that could make moves on Friday. The Company has been referred to as the "Priceline of Pot" by several sources, and similarly to the site which provides travel deals, Leafbuyer is the most comprehensive online source for cannabis deals and specials.

  • Here Are Some of GW Pharmaceuticals’ Key Growth Drivers
    Market Realist13 days ago

    Here Are Some of GW Pharmaceuticals’ Key Growth Drivers

    Cannabis Stock GW Pharmaceuticals Growing Steadily in January (Continued from Prior Part) ## Growth drivers The US FDA (Food and Drug Administration) confirmed GW Pharmaceuticals’ (GWPH) Epidiolex seven-year orphan drug exclusivity. The company anticipates a six-month extension for orphan drug exclusivity for pediatric patients. The USPTO granted major favorable patents associated with the use of CBD in epilepsy. The patents include claims for certain seizure types related to Dravet syndrome and LGS. The patents of GW Pharmaceuticals’ Cannabinoids will expire only after 2035. The market exclusivity, orphan drug exclusivity, and patents are expected to boost Epidiolex’s growth in 2019 and beyond. ## Growth opportunities GW Pharmaceuticals completed three phase 3 trials in Europe with Sativex (nabiximos), which all produced positive results. GW Pharmaceuticals targets Sativex approval for the treatment of multiple sclerosis spasticity. The company received regulatory approval in 25 countries outside the US for the treatment of individuals with spasticity associated with multiple sclerosis. GW Pharmaceuticals is conducting research for evaluating the potential of Sativex for the treatment of schizophrenia and other neurological disorders. GW Pharmaceuticals conducted phase 2 trials of CBD:THC for the evaluation of its efficacy in the treatment of Glioblastoma. GW Pharmaceuticals received an orphan drug designation from the US FDA and EMA (European Medicines Agency) for CBD:THC for the treatment of Glioblastoma. GW Pharmaceuticals has also completed a phase 1 trial of its Neonatal Hypoxic-Ischemic Encephalopathy intravenous CBD program. The company anticipates initiating a phase 2 trial during the first half of 2019. THC could boost the company’s growth in the long term. The growth of GW Pharmaceuticals could boost the share prices of the Horizons Marijuana Life Sciences Index ETF (HMLSF). GW Pharmaceuticals makes up ~9.27% of HMLSF’s total portfolio holding. Browse this series on Market Realist: * Part 1 - GW Pharmaceuticals Has Already Soared 23% in January * Part 2 - A Look into GW Pharmaceuticals’ Revenue Trends * Part 3 - How GW Pharmaceuticals’ Earnings Are Trending

  • How GW Pharmaceuticals’ Earnings Are Trending
    Market Realist13 days ago

    How GW Pharmaceuticals’ Earnings Are Trending

    Cannabis Stock GW Pharmaceuticals Growing Steadily in January (Continued from Prior Part) ## Earnings trends In fiscal 2018, GW Pharmaceuticals (GWPH) reported net income and EPS of -$295.2 million and -$0.88, respectively, compared to -$170.5 million and -$0.56 in the prior year. In the fourth quarter of 2018, GW Pharmaceuticals reported net income and EPS of -$79.9 million and -$0.23, respectively, compared to -$53.9 million and -$0.18 in the same period the prior year. ## Expenditure trends In fiscal 2018, GW Pharmaceuticals (GWPH) reported cost of product sales of $6.0 million compared to $4.5 million in fiscal 2017. In fiscal 2018, the company’s R&D (research and development) and SG&A (selling, general, and administrative) expenses amounted to $153.7 million and $141.8 million, respectively, compared to $112.2 million and $58.0 million in fiscal 2017. ## Growth drivers GW Pharmaceuticals’ Epidiolex demonstrated a positive result and achieved the primary endpoint in a phase 3 clinical trial that evaluated the efficacy parameters of the drug for the treatment of Dravet syndrome. In the clinical trial, both the doses of Epidiolex (10 mg/kg/day and 20 mg/kg/day) demonstrated statistically significant improvements in the secondary endpoint parameters compared to a placebo therapy. GW Pharmaceuticals also completed patient recruitment for its phase 3 trial of Epidiolex for the evaluation of its safety and efficacy parameters for the treatment of individuals with Tuberous Sclerosis Complex. The company anticipates data from the clinical trial in the first half of 2019 and expects submission of a supplemental new drug application (or sNDA) to the FDA (Food and Drug Administration) in the second half of 2019. The label expansion of Epidiolex could significantly boost the sales growth of the drug. Continue to Next Part Browse this series on Market Realist: * Part 1 - GW Pharmaceuticals Has Already Soared 23% in January * Part 2 - A Look into GW Pharmaceuticals’ Revenue Trends * Part 4 - Here Are Some of GW Pharmaceuticals’ Key Growth Drivers

  • A Look into GW Pharmaceuticals’ Revenue Trends
    Market Realist13 days ago

    A Look into GW Pharmaceuticals’ Revenue Trends

    Cannabis Stock GW Pharmaceuticals Growing Steadily in January (Continued from Prior Part) ## Revenue trends In the fourth quarter of fiscal 2018, GW Pharmaceuticals (GWPH) generated revenues of $2.42 million compared to $2.45 million in the same period the prior year, reflecting ~1% YoY growth. In fiscal 2018, GW Pharmaceuticals’ net revenues grew ~15.75% YoY to reach $12.74 from $11.00. In the fourth quarter of 2018, GW Pharmaceuticals generated revenues of $10.5 million from product sales compared to $8.0 million in the same period the prior year, reflecting ~32% YoY growth. Wall Street analysts estimate that GW Pharmaceuticals will generate revenues of $8.8 million in the first quarter of fiscal 2019, which represents ~15.75% YoY growth. Analysts also estimate that GW Pharmaceuticals’ net revenues in fiscal 2019 will be around $122.66 million. GW Pharmaceuticals is strengthening its supply chain of Epidiolex. GW Pharmaceuticals’ regulatory filing for approval of Epidiolex in the European market is under review by the European Medicines Agency (or EMA). The company anticipates the EMA’s decision by the first quarter of fiscal 2019. The approval of the drug in the European market could significantly boost the revenue growth of GW Pharmaceuticals. ## Peers’ performance Cara Therapeutics (CARA) and Insys Therapeutics (INSY), GW Pharmaceuticals’ peers in the medical cannabis market, reported revenues of $5.0 million and $18.35 million, respectively, in the third quarter of fiscal 2018. Wall Street analysts estimate that Cara Therapeutics and Insys Therapeutics will report net revenues of $10.9 million and $83.74 million, respectively, in fiscal 2018. The revenue growth of GW Pharmaceuticals, Cara Therapeutics, and Insys Therapeutics could boost the ETFMG Alternative Harvest ETF (MJ). GW Pharmaceuticals, Cara Therapeutics, and Insys Therapeutics make up ~5.95%, ~1.52%, and ~1.64% of MJ’s total portfolio holding. In the next article, we’ll discuss GW Pharmaceuticals’ other earnings and operational expenditure trends. Continue to Next Part Browse this series on Market Realist: * Part 1 - GW Pharmaceuticals Has Already Soared 23% in January * Part 3 - How GW Pharmaceuticals’ Earnings Are Trending * Part 4 - Here Are Some of GW Pharmaceuticals’ Key Growth Drivers

  • GW Pharmaceuticals Has Already Soared 23% in January
    Market Realist13 days ago

    GW Pharmaceuticals Has Already Soared 23% in January

    Cannabis Stock GW Pharmaceuticals Growing Steadily in January ## Stock performance On January 9, GW Pharmaceuticals (GWPH) stock rose ~1.81% to reach $119.54 from its prior day close of $117.41 on January 8. On January 7, the company’s stock price grew ~5.31% to reach $114.66 from its prior day close of $108.66 on January 4, 2019. On January 4, the company’s stock grew ~9.22% to reach $108.88 from its prior day close of $99.69 on January 3, 2019. GW Pharmaceuticals’ price of $119.54 on January 9 represents ~23% growth in the first six trading days of January 2, and this price is 33% below its 52-week high of $179.65 on September 27, 2018. On December 27, 2018, the company hit its 52-week low of $90.14. ## About GW Pharmaceuticals GW Pharmaceuticals is focused on the innovation, development, and commercialization of therapies from the company’s proprietary cannabinoid products. GW Pharmaceuticals’ Epidiolex oral solution has already received the FDA (Food and Drug Administration) approval for the treatment of individuals aged above two years with seizures related to Lennox-Gastaut syndrome or Dravet Syndrome. ## Analysts’ recommendations Of 13 analysts tracking GW Pharmaceuticals (GWPH) in January 2019, three of them recommended a “strong buy,” while eight analysts recommended a “buy” rating. One analyst recommended a “hold” rating, while one analyst recommended a “strong sell” for GW Pharmaceuticals in January. On January 10, GW Pharmaceuticals had a consensus 12-month target price of $173.17, which represents a ~44.86% return on investment over the next 12 months of this year. ## Peer ratings Of the five analysts tracking Supreme Cannabis Company (SPRWF) in January 2019, two of them recommended a “strong buy,” while three analysts recommended a “buy” rating. In January 2019, of the 11 analysts tracking Canopy Growth (CGC), two of them recommended a “strong buy,” seven recommended a “buy,” one recommended a “hold,” and one recommended a “sell” rating. Continue to Next Part Browse this series on Market Realist: * Part 2 - A Look into GW Pharmaceuticals’ Revenue Trends * Part 3 - How GW Pharmaceuticals’ Earnings Are Trending * Part 4 - Here Are Some of GW Pharmaceuticals’ Key Growth Drivers

  • Zacks Market Edge Highlights: Tilray, Constellation Brands, Altria and GW Pharmaceuticals
    Zacks14 days ago

    Zacks Market Edge Highlights: Tilray, Constellation Brands, Altria and GW Pharmaceuticals

    Zacks Market Edge Highlights: Tilray, Constellation Brands, Altria and GW Pharmaceuticals

  • ACCESSWIRE14 days ago

    4 Marijuana Stocks Setting The Stage On Thursday (1/10/19)

    CORAL GABLES, FL / ACCESSWIRE / January 10, 2019 / The way people receive health care, including how the medical field continues its integration of medical marijuana, is evolving. As public opinion surrounding cannabis becomes increasingly more favorable, marijuana stocks may begin to present an appealing opportunity for investors looking into the nascent sector. Premier Health Group (OTC:PHGRF) (CSE:PHGI), OrganiGram Holdings Inc (OGRMF), GW Pharmaceuticals Plc (GWPH), and Aphria Inc (APHA) represent 4 pot stocks that are heating up on Thursday.

  • The Wall Street Journal14 days ago

    [$$] Health-Care CEOs Outline Strategies at J.P. Morgan Conference

    One of the biggest health conferences of the year for investors, the J.P. Morgan Health-Care Conference, is taking place this week in San Francisco. BioMarin Pharmaceutical Inc. CEO Jean-Jacques Bienaimé said he would consider pursuing installment payment arrangements for the biotech’s experimental gene therapy for hemophilia. At the conference, Mr. Bienaimé told the Wall Street Journal that the one-time infusion, Valrox, is likely to cost in the millions because studies have shown it can eliminate bleeding episodes in patients, and current hemophilia treatments taken chronically can cost millions over several years.